Physician profile
Evan Michael Lapinsky
NPI 1134486046
$1,634.39
in general payments reported to CMS, 2019-2025
31 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $317 · 2021: $94.49 · 2022: $87.99 · 2023: $114 · 2024: $284 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048 · Education: $87.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.54 |
| Education | $87.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $267.30 | 2020-2025 | Imfinzi, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $183.45 | 2022-2025 | |
| Amgen INC. | $165.01 | 2020-2022 | |
| Genentech USA, INC. | $112.45 | 2022-2025 | Polivy, Lunsumio |
| Incyte Corporation | $88.36 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $79.59 | 2021-2025 | Trodelvy |
| Pfizer INC. | $74.39 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.34 | 2024-2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $48.22 | 2020-2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $45.44 | 2025 | Onivyde |
| Puma Biotechnology, INC. | $41.68 | 2020 | |
| Astellas Pharma US INC | $41.26 | 2024-2025 | Vyloy |
| Genzyme Corporation | $39.32 | 2022-2025 | |
| Celgene Corporation | $38.47 | 2024 | Reblozyl |
| Lilly USA, LLC | $34.09 | 2021-2023 | Verzenio, Jaypirca |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $33.59 | 2024 | Epkinly |
| Geron Corporation | $25.79 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $22.84 | 2025 | Ojjaara |
| Syndax Pharmaceuticals, INC. | $22.75 | 2025 | Revuforj |
| Beone Medicines USA, INC. | $21.98 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $21.34 | 2025 | Xpovio |
| Beigene USA, INC. | $21.27 | 2020 | |
| Abbvie INC. | $20.22 | 2025 | |
| Pharmacosmos Therapeutics INC. | $18.23 | 2021 | |
| Deciphera Pharmaceuticals INC. | $17.69 | 2025 | Romvimza, Qinlock |
| Daiichi Sankyo INC. | $16.34 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.56 | 2020 | |
| Merck Sharp & Dohme LLC | $14.93 | 2024 | Keytruda |
| Eisai INC. | $14.49 | 2020 | |
| Dova Pharmaceuticals | $13.33 | 2020 | |
| Epizyme, INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Lapinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.